ADDvise Group AB receives SEK 27.8 million through the warrants of series 2019/2021 – Regulatory information

10-02-2021   Regulatory press release

Holders of warrants of series 2019/2021 subscribed for 42,787,137 warrants, corresponding to 99.41 percent of the outstanding warrants, for subscription of 42,787,137 shares of series B at the subscribtion price of SEK 0.65. Through the exercise of the warrants, ADDvise receives SEK 27,811,639 before issue costs.


During the first quarter of 2019, ADDvise carried out a rights issue of units, consisting of one (1) newly issued series B share and one (1) warrant of series 2019/2021. Each warrant of series 2019/2021 entitled the holder to subscribe for one (1) new B share in ADDvise. The subcription period ran January 25, 2021 and February 8, 2021.

Exercised warrants have been replaced with interim shares (IA) pending registration at Bolagsverket. The conversion of interim shares into shares of series B is expected to take place within approximately three weeks.

Complete terms and conditions for the warrants are available on the Company's website,

Number of shares and share capital

Through the exercise of the warrants, the number of shares in ADDvise increases by 42,787,137 shares, from 96,913,631 to 139,700,768 shares. The share capital increases by SEK 4,278,713,7 from SEK 9,691,363.1 to SEK 13,970,076,8.

For existing shareholders who have not exercised any warrants of series 2019/2021, the dilution amounts to approximately 31.08 percent.


Mangold Fondkommission is financial adviser and Advokatfirman Schjødt is legal advisor to ADDvise in connection with the exercise of warrants of series 2019/2021.

For questions regarding the warrants, please contact:

Mangold Fondkommission AB

Tel: +46 8 5030 1595


For further information:

Hanna Myhrman, General Counsel
Tel: +46 709 82 92 23

Important information:

This information is by ADDvise Group AB required to disclose under the EU Market Abuse Regulation. The information was submitted for publication on 10 February 2021 at 08:00 CET.

About ADDvise

ADDvise Group AB (publ) is a leading supplier of equipment to healthcare and research facilities. The group consists of approximately 10 subsidiaries organized into two business areas, Lab and Healthcare. Sales are global. The Group has a clear acquisition strategy with the aim of raising shareholder value and expand the business - both geographically and product wise. ADDvise Group's shares are listed on Nasdaq First North Growth Market and Mangold Fondkommission AB, +46 8 503 015 50,, is the Company's Certified Adviser. Additional information is available at

Latest press releases

ADDvise completes the acquisition of MRC Systems FZE


ADDvise Group AB (publ) (”ADDvise”) has today completed the acquisition of all shares in MRC Systems FZE (”MRC”). The signing of the share purchase agreement has been communicated to the market via a press release on 16 February 2021. The total purchase price amounts to USD 8.00 million, of which USD 4.50 million has been…

ADDvise signs Letter of Intent to acquire Medisuite, LLC


ADDvise Group AB (publ) has signed a Letter of Intent with the shareholders of Medisuite, LLC (”Medisuite”) regarding an acquisition of 100 percent of the shares in Medisuite. Medisuite is an American online pharmacy that specializes in medication for men’s health. The prescription medication that is marketed by Medisuite is mainly used for treatment of…

ADDvise Group to redeem its outstanding up to SEK 240,000,000 senior secured callable bonds


ADDvise Group AB (publ) (“ADDvise") hereby announces that ADDvise’s up to SEK 240,000,000 senior unsecured callable floating rate bonds with ISIN SE0010298166 (the "Bonds"), will be redeemed in advance in accordance with Clause 8.3 (Voluntary total redemption (call option)) of the terms and conditions of the Bonds. The redemption date will be 18 June 2021.…